Accepted Manuscript

Pre-clinical Disease Models in Drug Toxicity Evaluation

Martyn L. Foster

PII: S2468-2020(16)30037-7

DOI: 10.1016/j.cotox.2017.06.001

Reference: COTOX 51

To appear in: Current Opinion in Toxicology

Received Date: 25 April 2017

Accepted Date: 1 June 2017

Please cite this article as: M.L. Foster, Pre-clinical Disease Models in Drug Toxicity Evaluation, *Current Opinion in Toxicology* (2017), doi: 10.1016/j.cotox.2017.06.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



An addition to routine toxicity assessment – not a replacement

Specific mechanistic hypothesis must be framed

sk-benefit analysis: does the eployment of the animal model ddress the hypothesis?





Pre-clinical Disease Models in Toxicity Testing



Evaluate predictive power of disease model





Understand resultant modulation of disease phenotype by compound and alignment to hypothesis

Understand commonalities and differences in target pathway responses

Download English Version:

https://daneshyari.com/en/article/8920260

Download Persian Version:

https://daneshyari.com/article/8920260

<u>Daneshyari.com</u>